title: Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
abstract: Pharmacokinetics of total platinum, 5-fluorouracil, l-folinic and d-folinic acid, and 5-methyltetrahydrofolate were studied in plasma from nine patients with advanced colorectal cancer treated with oxaliplatin (20 mg/m2/day), 5-fluorouracil (600 mg/m2/day), and folinic acid (300 mg/m2/day). Drugs were administered with a programmable-in-time pump by continuous infusion for 5 days. We compared two drug delivery schedules: constant rate versus chronomodulated rate with peak of oxaliplatin at 4 pm and peak of 5-fluorouracil and folinic acid at 4 am. In the chronomodulated schedule, plasma concentrations of the drugs paralleled the pump functioning: maximum platinum concentration near 4 pm, and maximum 5-fluorouracil and folate concentrations near 4 am. When drugs were administered at a constant rate, mean plasma concentration of 5-fluorouracil varied in a circadian manner each treatment day, that is, a peak at 4 am (approximately 800 ng/ml) and a trough at 1 pm (approximately 100 ng/ml). Mean plasma levels of total platinum and folate compounds increased over the first 24 hours. Total platinum mean level and that of the inactive d-folinic acid isomer reached a constant plasma concentration, whereas biologically active folates exhibited circadian variation in their plasma concentrations (peak around 7 am, trough near 6 pm, and amplitude approximately 10%). Severe mucositis was exhibited by all four patients on the flat schedule, but only by one on the chronomodulated schedule (p < 0.008). Individual pharmacokinetic and toxicity data showed that patients with circadian rhythms in 5-fluorouracil concentrations were least sensitive to 5-fluorouracil-related toxicity. Thus amplification or induction of such rhythm in 5-fluorouracil exposure may permit dose escalation.
authors.affiliation: Laboratoire Rythmes biologiques et Chronothérapeutique, ICIG, Hôpital Paul Brousse, Villejuif, France.
authors.forename: G
authors.initials: G
authors.lastname: Metzger
authors.forename: C
authors.initials: C
authors.lastname: Massari
authors.forename: M C
authors.initials: MC
authors.lastname: Etienne
authors.forename: M
authors.initials: M
authors.lastname: Comisso
authors.forename: S
authors.initials: S
authors.lastname: Brienza
authors.forename: Y
authors.initials: Y
authors.lastname: Touitou
authors.forename: G
authors.initials: G
authors.lastname: Milano
authors.forename: G
authors.initials: G
authors.lastname: Bastian
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
authors.forename: F
authors.initials: F
authors.lastname: Lévi
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D002940:Circadian Rhythm; D015179:Colorectal Neoplasms / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005492:Folic Acid / Q000097:blood; D006801:Humans; D007260:Infusion Pumps; D002955:Leucovorin / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000187:drug effects; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077150:Oxaliplatin; D013237:Stereoisomerism; D013280:Stomatitis / Q000139:chemically induced; D013763:Tetrahydrofolates / Q000097:blood
chemical_list: D009944:Organoplatinum Compounds; D013763:Tetrahydrofolates; D000077150:Oxaliplatin; D005492:Folic Acid; D002955:Leucovorin; C005984:5-methyltetrahydrofolate; D005472:Fluorouracil